Federal Contractor Profile
Revagenix INC
Federal contracting record: $55M obligated across 2 awards from 1 agencies, FY 2020–2026.
$55M
Total Obligated
2
Award Records
1
Agencies Served
1
NAICS Codes
Company Profile
Parent UEI (Unique Entity Identifier)
D98QFZUPFXJ9
CAGE Code
8B1Y9
Address
1729 DOLAN AVE, SAN MATEO, CA, 944012126
First Federal Award
Jun 29, 2020
Most Recent Award
Jul 10, 2026
Federal Sales Analytics
Toggle between trend, agency drilldown, and treemap. Use the period selector to focus the time window.
Hover any bar for YoY change + award count. Current fiscal year shown at reduced opacity (partial year).
Top Federal Agencies
- Department of Health and Human Services$55M
100.0% of total obligations
Top NAICS Activity
- 541715$55M
RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)
2 awards
Recent Federal Awards
| Date | Agency | NAICS | Description | Amount |
|---|---|---|---|---|
| May 6, 2026 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541715 | A NOVEL LPXC INHIBITOR WITH PAN-RESISTANT PSEUDOMONAS AND BURKHOLDERIA ACTIVITY. | $327K |
| Mar 23, 2026 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541715 | A NOVEL LPXC INHIBITOR WITH PAN-RESISTANT PSEUDOMONAS AND BURKHOLDERIA ACTIVITY. | $10.0M |
| Dec 30, 2025 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541715 | A NOVEL LPXC INHIBITOR WITH PAN-RESISTANT PSEUDOMONAS AND BURKHOLDERIA ACTIVITY. | $1.8M |
| Dec 23, 2025 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541715 | TO SELECT A NOVEL SMALL MOLECULE ANTIBIOTIC FOR CLINICAL DEVELOPMENT AND ADVANCE IT THROUGH IND FILING AND PHASE 1 CLINICAL STUDIES. | $2.1M |
| Apr 22, 2025 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541715 | TO SELECT A NOVEL SMALL MOLECULE ANTIBIOTIC FOR CLINICAL DEVELOPMENT AND ADVANCE IT THROUGH IND FILING AND PHASE 1 CLINICAL STUDIES. | $671K |
| Sep 10, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541715 | A NOVEL LPXC INHIBITOR WITH PAN-RESISTANT PSEUDOMONAS AND BURKHOLDERIA ACTIVITY. | $1.8M |
| Aug 5, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541715 | A NOVEL LPXC INHIBITOR WITH PAN-RESISTANT PSEUDOMONAS AND BURKHOLDERIA ACTIVITY. | $2.7M |
| Aug 1, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541715 | TO SELECT A NOVEL SMALL MOLECULE ANTIBIOTIC FOR CLINICAL DEVELOPMENT AND ADVANCE IT THROUGH IND FILING AND PHASE 1 CLINICAL STUDIES. | $3.8M |
| Mar 1, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541715 | A NOVEL LPXC INHIBITOR WITH PAN-RESISTANT PSEUDOMONAS AND BURKHOLDERIA ACTIVITY. | $6.7M |
| Feb 23, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541715 | TO SELECT A NOVEL SMALL MOLECULE ANTIBIOTIC FOR CLINICAL DEVELOPMENT AND ADVANCE IT THROUGH IND FILING AND PHASE 1 CLINICAL STUDIES. | $2.8M |
| Jan 13, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541715 | TO SELECT A NOVEL SMALL MOLECULE ANTIBIOTIC FOR CLINICAL DEVELOPMENT AND ADVANCE IT THROUGH IND FILING AND PHASE 1 CLINICAL STUDIES. | $5.1M |
| Sep 22, 2022 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541715 | A NOVEL LPXC INHIBITOR WITH PAN-RESISTANT PSEUDOMONAS AND BURKHOLDERIA ACTIVITY. | $4.8M |
| Jul 19, 2022 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541715 | TO SELECT A NOVEL SMALL MOLECULE ANTIBIOTIC FOR CLINICAL DEVELOPMENT AND ADVANCE IT THROUGH IND FILING AND PHASE 1 CLINICAL STUDIES. | $5.4M |
| Mar 29, 2022 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541715 | TO SELECT A NOVEL SMALL MOLECULE ANTIBIOTIC FOR CLINICAL DEVELOPMENT AND ADVANCE IT THROUGH IND FILING AND PHASE 1 CLINICAL STUDIES. | $1.3M |
| Jul 12, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541715 | TO SELECT A NOVEL SMALL MOLECULE ANTIBIOTIC FOR CLINICAL DEVELOPMENT AND ADVANCE IT THROUGH IND FILING AND PHASE 1 CLINICAL STUDIES. | $2.7M |
| Jun 29, 2020 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541715 | TO SELECT A NOVEL SMALL MOLECULE ANTIBIOTIC FOR CLINICAL DEVELOPMENT AND ADVANCE IT THROUGH IND FILING AND PHASE 1 CLINICAL STUDIES. | $3.0M |
Want to win work like Revagenix INC?
Their contracts will eventually end — and when they do, the government has to award that work again. Mindy tells you up to a year early, so you can be ready to compete for it.